{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"PRISM-1","nct_id":"NCT06608927","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prism-1-nct06608927. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PRISM-1","arms":[{"description":"Quemliclustat, nab-paclitaxel and gemcitabine will be administered by IV infusion","label":"Arm A (Experimental Arm)","type":"EXPERIMENTAL"},{"description":"Placebo, nab-paclitaxel and gemcitabine will be administered by IV infusion","label":"Arm B (Comparator Arm)","type":"PLACEBO_COMPARATOR"}],"collaborators":["Taiho Pharmaceutical Co., Ltd."],"completion_date":{"date":"2030-11-30","type":"ESTIMATED"},"conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":{"count":610,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Quemliclustat","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-29","lead_sponsor":"Arcus Biosciences, Inc.","official_title":"A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 72 months"}],"references":[],"start_date":{"date":"2024-12-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT06608927"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prism-1-nct06608927"}